AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn
Source: SeekingAlpha
2025-06-13 13:45:12 ET
Investment Thesis
I grant AbCellera Biologics Inc. ( ABCL ) a Hold rating. In my opinion, the critical aspect of the company is whether it will have sufficient financial resources until at least one of its agreements with other firms, or its drug development program, yields results, assuming that these agreements or programs are successful....
Read the full article on Seeking Alpha
For further details see:
AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn
Charles River Laboratories International Inc.
NASDAQ: CRL
CRL Trading
-1.86% G/L:
$154.76 Last:
369,170 Volume:
$155.62 Open:
CRL Latest News
March 02, 2026 08:00:00 am
Charles River Laboratories to Present at TD Cowen and Barclays Conferences
CRL Stock Data
$8,919,319,809
48,575,670
0.75%
260
N/A
Biotechnology & Life Sciences
Healthcare
US
Wilmington
